Verrica Pharmaceuticals Presents Clinical Studies Data at 2021 Winter Clinical Dermatology Conference

Verrica Pharmaceuticals Inc

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced the presentation of positive data from post-hoc pooled analyses of the pivotal Phase 3 CAMP trials evaluating the safety and efficacy of VP-102, Verrica’s lead product candidate, in molluscum contagiosum (molluscum) in specific body regions at each visit. The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.

“We are pleased to present further positive data supporting VP-102 as a potentially safe and efficacious treatment for molluscum,” said Gary Goldenberg, M.D., Chief Medical Officer at Verrica. “VP-102, our lead candidate, continues to demonstrate positive results as we advance development of the program in molluscum, external genital warts and common warts, three of the largest unmet needs in medical dermatology.”

READ:  Vishay Intertechnology Enhances Thick Film Chip Resistor in 1206 Case Size With Higher 0.5 W Power Rating

Results showed that VP-102-treated participants with lesions in the upper extremities, head/neck, back/buttocks, and chest/abdomen at baseline showed statistically significantly higher rates of complete clearance in those regions compared to vehicle beginning after the first treatment (Visit 2; Day 21) through the EOS visit. VP-102-treated participants with lesions in the lower extremities at baseline showed statistically significantly higher complete clearance rates compared to vehicle-treated participants beginning after two treatments (Visit 3; Day 42) through the EOS visit (Day 84). The incidence of adverse events was similar in all body regions.

Data were also presented from Verrica’s Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW). Results showed that treatment with VP-102 resulted in a statistically significantly higher complete clearance rate of all EGW compared to vehicle at Visit 4 (Day 63) and at the End of Treatment Visit (Day 84) regardless of drug exposure duration (6 or 24 hours). Incidence of adverse events were primarily mild to moderate and similar across VP-102 drug exposure groups.

READ:  Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

The presentations are available on the Publications section of Verrica’s website at

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.